SHANGHAI – Privately held Huya Bioscience International, of San Diego, has signed a strategic partnership with the Changzhou Center for Biotech Development (CZCBD) for the advancement of innovative drug and biomarker candidates.
NEW DELHI – India's Central Drugs Standard Control Organisation (CDSCO) announced plans to set up an online system for submission of information on clinical trials.
Polio was declared an eradicable disease in 1988, and although the global polio eradication initiative missed its original goal of wiping the disease off the face of the planet by 2000, it certainly seems possible to get there.
Basilea Pharmaceutica Ltd., of Basel, Swizterland, said the EMA accepted the marketing authorization application seeking approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis (zygomycosis) in adults. Basilea's co-development partner, Astellas Pharma Inc., of Tokyo, submitted a new drug application to the FDA in July.
SHANGHAI – China Biologic Inc., of Beijing, has topped up its controlling equity interest by 20 percent in Guizhou Taibang Biological Products Co. Ltd., in a deal valued at $87.1 million.
HONG KONG – A Chinese pharmaceutical company and its American partner have announced their plan to accelerate collaboration on the development of cancer drugs, with an eye on launching clinical trials in China soon.
HONG KONG – The first human trial of a new vaccine based on virus-like particles (VLPs) suggests it is safe and effective against the rapidly emerging mosquito-borne chikungunya virus, researchers reported in the Aug. 15 early online edition of The Lancet.
SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases.
HONG KONG – Several major players in China's biopharmaceutical industry have released their second quarter and first-half 2014 financial results, with some companies having a better year than others so far.
NEW DELHI – Indian biopharma company Vyome Biosciences raised almost $8 million in a second round of fundraising as part of a push to develop treatments for hard-to-treat skin conditions such as acne, persistent dandruff and bacterial and fungal skin infections.
RSS